These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26824502)

  • 1. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.
    Liu S; Nikanjam M; Kurzrock R
    Oncotarget; 2016 Mar; 7(10):11310-20. PubMed ID: 26824502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.
    Nikanjam M; Liu S; Kurzrock R
    Int J Cancer; 2016 Nov; 139(9):2135-41. PubMed ID: 27389805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.
    Nikanjam M; Liu S; Yang J; Kurzrock R
    Oncologist; 2017 May; 22(5):576-584. PubMed ID: 28424323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.
    Nikanjam M; Patel H; Kurzrock R
    Oncoimmunology; 2017; 6(8):e1338997. PubMed ID: 28920006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination phase I trials].
    Masuda N
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):219-25. PubMed ID: 8611050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. At the right dose: personalised (N-of-1) dosing for precision oncology.
    Nikanjam M; Kato S; Sicklick JK; Kurzrock R
    Eur J Cancer; 2023 Nov; 194():113359. PubMed ID: 37832506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego.
    Nikanjam M; Tinajero J; McGann M; Li J; Yang J; Shen F; Sicklick JK; Kato S; Capparelli E; Kurzrock R
    J Hematol Oncol Pharm; 2023 Feb; 13(1):19-25. PubMed ID: 36998525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
    Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward rapamycin analog (rapalog)-based precision cancer therapy.
    Meng LH; Zheng XF
    Acta Pharmacol Sin; 2015 Oct; 36(10):1163-9. PubMed ID: 26299952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
    Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
    J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
    Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
    Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
    Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
    Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
    Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I studies of drug combinations.
    Verweij J; Disis ML; Cannistra SA
    J Clin Oncol; 2010 Oct; 28(30):4545-6. PubMed ID: 20855831
    [No Abstract]   [Full Text] [Related]  

  • 19. Computational oncology--mathematical modelling of drug regimens for precision medicine.
    Barbolosi D; Ciccolini J; Lacarelle B; Barlési F; André N
    Nat Rev Clin Oncol; 2016 Apr; 13(4):242-54. PubMed ID: 26598946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.